Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.

Pivotal data set the stage for slightly delayed US accelerated approval filing.

But first it will need to identify the optimal dose in first-line small-cell lung cancer.

Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.

So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.

But results come from a curated dataset, with no in-trial comparator.